As Chinese drugmakers churn out a record number of novel therapies, industry experts urge an overhaul of pricing, insurance and medical infrastructure to ensure new treatments reach patients
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Caixin hosts a panel discussion on innovative drug R&D at the 2026 Summer Davos on June 23, 2026 in Dalian, Liaoning. Photo: Zhou Xinda/Caixin
Despite efforts to ease pressure on state-run healthcare, commercial insurers covered just 7.8% of the country’s innovative drug…
‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.
A globally innovative narcolepsy drug makes its debut in China, while AI startup Anthropic agrees to a record $1.5 billion…
Multinational drugmakers are returning to China’s centralized procurement program after rule changes gave originator medicines a…
With more drugs in clinical trials than any other country, Chinese drugmakers are now shifting focus to the high-risk,…
China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision…
